Patents by Inventor Denise Williams
Denise Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220248883Abstract: This disclosure relates to a pillow cover with a vertical pocket on the front side for a neck pillow made up of foam. The invention is a rectangular shaped bed pillowcase, with a u-shaped neck pillow for elevating the head while sleeping. This pillow cover is easily portable and designed to fit all types and sizes of pillows.Type: ApplicationFiled: February 8, 2021Publication date: August 11, 2022Inventor: Jennifer Denise Williams
-
Publication number: 20220104594Abstract: A bag for storing one or more of clothing, wig, and hair extensions is provided. The bag may include first and second front top sections; first and second front middle sections; first and second front bottom sections; a back section; and a zipper. In a closed state the zipper is configured to join the first and second front top sections; the first and second front middle sections; and the first and second front bottom sections. The combination of the first and second front top sections, the first and second front middle sections, and the first and second front bottom sections, in the closed state, are configured to form an hourglass shape; and the back section overlaps the first and second front top sections, the first and second front middle sections, and the first and second front bottom sections when those sections are configured to form the hourglass shape.Type: ApplicationFiled: October 1, 2021Publication date: April 7, 2022Inventor: STEPHANIE DENISE WILLIAMS
-
Patent number: 10501556Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.Type: GrantFiled: August 15, 2017Date of Patent: December 10, 2019Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
-
Publication number: 20170369568Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: August 14, 2017Publication date: December 28, 2017Applicant: E. R. SQUIBB & SONS, L.L.C.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David J. King, David B. Passmore
-
Publication number: 20170342165Abstract: Methods for treating a cocaine-related disorder in an individual de administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.Type: ApplicationFiled: August 15, 2017Publication date: November 30, 2017Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
-
Patent number: 9765141Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: March 21, 2014Date of Patent: September 19, 2017Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 9758593Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.Type: GrantFiled: April 20, 2007Date of Patent: September 12, 2017Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
-
Publication number: 20140199328Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: March 21, 2014Publication date: July 17, 2014Applicant: Medarex, LLCInventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 8722870Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: June 4, 2013Date of Patent: May 13, 2014Assignee: Medarex, L.L.C.Inventors: Alison J. Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 8670999Abstract: Systems and methods for managing medical information for medical service providers are provided. Personnel are able to manage and track workflow operations, evaluate profitability, and maintain records in an integrated and streamlined manner by executing various modules of a software application.Type: GrantFiled: March 29, 2012Date of Patent: March 11, 2014Assignee: McKesson Financial HoldingsInventors: Kristi Innocenti Berzansky, Denise Williams, Binny John, Kruti Goswami, Paras Desai, Shabari Madappa, Hamsa Konanur, David Barber
-
Publication number: 20130254912Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: June 4, 2013Publication date: September 26, 2013Applicant: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 8475797Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: August 16, 2011Date of Patent: July 2, 2013Assignee: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josphine M Cardelli, David King, David Passmore
-
Publication number: 20120253839Abstract: Systems and methods for managing medical information for medical service providers are provided. Personnel are able to manage and track workflow operations, evaluate profitability, and maintain records in an integrated and streamlined manner by executing various modules of a software application.Type: ApplicationFiled: March 29, 2012Publication date: October 4, 2012Applicant: MCKESSON FINANCIAL HOLDINGS LIMITEDInventors: Kristi Innocenti Berzansky, Binny John, Hamsa Konanur, David Barber, Paras Desai, Kruti Goswami, Denise Williams, Shabari Madappa
-
Patent number: 8173779Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.Type: GrantFiled: November 8, 2010Date of Patent: May 8, 2012Assignee: Schering CorporationInventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
-
Publication number: 20110300145Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: August 16, 2011Publication date: December 8, 2011Applicant: MEDAREX, INCInventors: ALISON WITTE, DENISE WILLIAMS, JOSEPHINE M. CARDARELLI, DAVID KING, DAVID PASSMORE
-
Patent number: 8025882Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: August 31, 2009Date of Patent: September 27, 2011Assignee: Medarex, Inc.Inventors: Alison J. Witte, Denise Williams, Josephine M. Cardarelli, David J. King, David B. Passmore
-
Publication number: 20110060130Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.Type: ApplicationFiled: November 8, 2010Publication date: March 10, 2011Inventors: YAN WANG, ROBERT GREENBERG, LEONARD PRESTA, JONATHAN A. PACHTER, JUDITH HAILEY, PETER BRAMS, DENISE WILLIAMS, MOHAN SRINIVASAN, DIANE FEINGERSH
-
Publication number: 20110014117Abstract: The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.Type: ApplicationFiled: June 25, 2008Publication date: January 20, 2011Inventors: Yan Wang, Jonathan A. Pachter, Judith Anne Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Mary Diane Feingersh
-
Patent number: D996818Type: GrantFiled: October 7, 2021Date of Patent: August 29, 2023Inventor: Stephanie Denise Williams
-
Patent number: D1005679Type: GrantFiled: May 6, 2023Date of Patent: November 28, 2023Inventor: Stephanie Denise Williams